Now showing items 1648-1667 of 4516

    • Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. 

      Gris-Oliver, A; Palafox, M; Monserrat, L; Brasó-Maristany, F; Òdena, A; Sánchez-Guixé, M; Ibrahim, YH; Villacampa, G; Grueso, J; Parés, M; Guzmán, M; Rodríguez, O; Bruna, A; Hirst, CS; Barnicle, A; de Bruin, EC; Reddy, A; Schiavon, G; Arribas, J; Mills, GB; Caldas, C; Dienstmann, R; Prat, A; Nuciforo, P; Razavi, P; Scaltriti, M; Turner, NC; Saura, C; Davies, BR; Oliveira, M; Serra, V (2020-07)
      <h4>Purpose</h4>AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen ...
    • Genetic and functional diversity of propagating cells in glioblastoma. 

      Piccirillo, SGM; Colman, S; Potter, NE; van Delft, FW; Lillis, S; Carnicer, M-J; Kearney, L; Watts, C; Greaves, M (2015-01)
      Glioblastoma (GBM) is a lethal malignancy whose clinical intransigence has been linked to extensive intraclonal genetic and phenotypic diversity and the common emergence of therapeutic resistance. This interpretation ...
    • Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10p21.2. 

      Studd, JB; Vijayakrishnan, J; Yang, M; Migliorini, G; Paulsson, K; Houlston, RS (2017-03-03)
      Despite high-hyperdiploid acute lymphoblastic leukaemia (HD-ALL) being the most common subgroup of paediatric ALL, its aetiology remains unknown. Genome-wide association studies have demonstrated association at 10q21.2. ...
    • Genetic characterisation of radiation-induced breast cancer in survivors of Hodgkin's lymphoma 

      Meier, M (2019-08-31)
      Hodgkin's lymphoma (HL) accounts for less than one percent of new cancer cases every year in the UK. Although historically HL patients had a poor prognosis, decades of treatments for this hematopoietic neoplasm have led ...
    • Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. 

      Went, M; Sud, A; Speedy, H; Sunter, NJ; Försti, A; Law, PJ; Johnson, DC; Mirabella, F; Holroyd, A; Li, N; Orlando, G; Weinhold, N; van Duin, M; Chen, B; Mitchell, JS; Mansouri, L; Juliusson, G; Smedby, KE; Jayne, S; Majid, A; Dearden, C; Allsup, DJ; Bailey, JR; Pratt, G; Pepper, C; Fegan, C; Rosenquist, R; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Einsele, H; Gregory, WM; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Nickel, J; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Walker, BA; Broyl, A; Davies, FE; Hansson, M; Goldschmidt, H; Dyer, MJS; Kaiser, M; Sonneveld, P; Morgan, GJ; Hemminki, K; Nilsson, B; Catovsky, D; Allan, JM; Houlston, RS (2018-12-21)
      The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma ...
    • Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. 

      Yang, Y; Wu, L; Shu, X; Lu, Y; Shu, X-O; Cai, Q; Beeghly-Fadiel, A; Li, B; Ye, F; Berchuck, A; Anton-Culver, H; Banerjee, S; Benitez, J; Bjørge, L; Brenton, JD; Butzow, R; Campbell, IG; Chang-Claude, J; Chen, K; Cook, LS; Cramer, DW; deFazio, A; Dennis, J; Doherty, JA; Dörk, T; Eccles, DM; Edwards, DV; Fasching, PA; Fortner, RT; Gayther, SA; Giles, GG; Glasspool, RM; Goode, EL; Goodman, MT; Gronwald, J; Harris, HR; Heitz, F; Hildebrandt, MA; Høgdall, E; Høgdall, CK; Huntsman, DG; Kar, SP; Karlan, BY; Kelemen, LE; Kiemeney, LA; Kjaer, SK; Koushik, A; Lambrechts, D; Le, ND; Levine, DA; Massuger, LF; Matsuo, K; May, T; McNeish, IA; Menon, U; Modugno, F; Monteiro, AN; Moorman, PG; Moysich, KB; Ness, RB; Nevanlinna, H; Olsson, H; Onland-Moret, NC; Park, SK; Paul, J; Pearce, CL; Pejovic, T; Phelan, CM; Pike, MC; Ramus, SJ; Riboli, E; Rodriguez-Antona, C; Romieu, I; Sandler, DP; Schildkraut, JM; Setiawan, VW; Shan, K; Siddiqui, N; Sieh, W; Stampfer, MJ; Sutphen, R; Swerdlow, AJ; Szafron, LM; Teo, SH; Tworoger, SS; Tyrer, JP; Webb, PM; Wentzensen, N; White, E; Willett, WC; Wolk, A; Woo, YL; Wu, AH; Yan, L; Yannoukakos, D; Chenevix-Trench, G; Sellers, TA; Pharoah, PDP; Zheng, W; Long, J (2019-02)
      DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains ...
    • The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. 

      O'Leary, B; Cutts, RJ; Liu, Y; Hrebien, S; Huang, X; Fenwick, K; André, F; Loibl, S; Loi, S; Garcia-Murillas, I; Cristofanilli, M; Huang Bartlett, C; Turner, NC (2018-11)
      CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence ...
    • Genetic losses in breast cancer: toward an integrated molecular cytogenetic map 

      Mao, X; Hamoudi, RA; Zhao, P; Baudis, M (2005-07-15)
      Breast cancer is the most common malignant disease in Caucasian women, but is less frequent in Chinese women. The molecular basis for such ethnical difference in disease pathogenesis remains unknown. To address this issue, ...
    • Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. 

      Hermanova, I; Zúñiga-García, P; Caro-Maldonado, A; Fernandez-Ruiz, S; Salvador, F; Martín-Martín, N; Zabala-Letona, A; Nuñez-Olle, M; Torrano, V; Camacho, L; Lizcano, JM; Talamillo, A; Carreira, S; Gurel, B; Cortazar, AR; Guiu, M; López, JI; Martinez-Romero, A; Astobiza, I; Valcarcel-Jimenez, L; Lorente, M; Arruabarrena-Aristorena, A; Velasco, G; Gomez-Muñoz, A; Suárez-Cabrera, C; Lodewijk, I; Flores, JM; Sutherland, JD; Barrio, R; de Bono, JS; Paramio, JM; Trka, J; Graupera, M; Gomis, RR; Carracedo, A (2020-06)
      Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form ...
    • Genetic mechanisms in squamous cell carcinoma of the head and neck. 

      Jefferies, S (2001-02)
      Genetic mechanisms in squamous cell carcinoma of the head and neck. This review aims to explore the genetic mechanisms involved in the development of squamous cell carcinoma of the head and neck (SCCHN). The epidemiology ...
    • Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. 

      Muranen, TA; Greco, D; Blomqvist, C; Aittomäki, K; Khan, S; Hogervorst, F; Verhoef, S; Pharoah, PDP; Dunning, AM; Shah, M; Luben, R; Bojesen, SE; Nordestgaard, BG; Schoemaker, M; Swerdlow, A; García-Closas, M; Figueroa, J; Dörk, T; Bogdanova, NV; Hall, P; Li, J; Khusnutdinova, E; Bermisheva, M; Kristensen, V; Borresen-Dale, A-L; NBCS Investigators; Peto, J; Dos Santos Silva, I; Couch, FJ; Olson, JE; Hillemans, P; Park-Simon, T-W; Brauch, H; Hamann, U; Burwinkel, B; Marme, F; Meindl, A; Schmutzler, RK; Cox, A; Cross, SS; Sawyer, EJ; Tomlinson, I; Lambrechts, D; Moisse, M; Lindblom, A; Margolin, S; Hollestelle, A; Martens, JWM; Fasching, PA; Beckmann, MW; Andrulis, IL; Knight, JA; kConFab/AOCS Investigators; Anton-Culver, H; Ziogas, A; Giles, GG; Milne, RL; Brenner, H; Arndt, V; Mannermaa, A; Kosma, V-M; Chang-Claude, J; Rudolph, A; Devilee, P; Seynaeve, C; Hopper, JL; Southey, MC; John, EM; Whittemore, AS; Bolla, MK; Wang, Q; Michailidou, K; Dennis, J; Easton, DF; Schmidt, MK; Nevanlinna, H (2017-05)
      <h4>Purpose</h4>CHEK2*1100delC is a founder variant in European populations that confers a two- to threefold increased risk of breast cancer (BC). Epidemiologic and family studies have suggested that the risk associated ...
    • Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. 

      Painter, JN; O'Mara, TA; Morris, AP; Cheng, THT; Gorman, M; Martin, L; Hodson, S; Jones, A; Martin, NG; Gordon, S; Henders, AK; Attia, J; McEvoy, M; Holliday, EG; Scott, RJ; Webb, PM; Fasching, PA; Beckmann, MW; Ekici, AB; Hein, A; Rübner, M; Hall, P; Czene, K; Dörk, T; Dürst, M; Hillemanns, P; Runnebaum, I; Lambrechts, D; Lambrechts, D; Amant, F; Annibali, D; Depreeuw, J; Vanderstichele, A; Goode, EL; Cunningham, JM; Dowdy, SC; Winham, SJ; Trovik, J; Hoivik, E; Werner, HMJ; Krakstad, C; Ashton, K; Otton, G; Proietto, T; Tham, E; Mints, M; Ahmed, S; Healey, CS; Shah, M; Pharoah, PDP; Dunning, AM; Dennis, J; Bolla, MK; Michailidou, K; Wang, Q; Tyrer, JP; Hopper, JL; Peto, J; Swerdlow, AJ; Burwinkel, B; Brenner, H; Meindl, A; Brauch, H; Lindblom, A; Chang-Claude, J; Couch, FJ; Giles, GG; Kristensen, VN; Cox, A; Zondervan, KT; Nyholt, DR; MacGregor, S; Montgomery, GW; Tomlinson, I; Easton, DF; Thompson, DJ; Spurdle, AB (2018-05)
      Epidemiological, biological, and molecular data suggest links between endometriosis and endometrial cancer, with recent epidemiological studies providing evidence for an association between a previous diagnosis of endometriosis ...
    • Genetic predisposition for multiple myeloma. 

      Pertesi, M; Went, M; Hansson, M; Hemminki, K; Houlston, RS; Nilsson, B (2020-03)
      Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic ...
    • Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism. 

      Studd, JB; Yang, M; Li, Z; Vijayakrishnan, J; Lu, Y; Yeoh, AE-J; Paulsson, K; Houlston, RS (2019-01)
      Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Genome-wide association studies have shown variation at 14q11.2 influences ALL risk. We sought to decipher causal variant(s) at 14q11.2 and the ...
    • Genetic predisposition to chronic lymphocytic leukemia 

      Law, PJ; Houlston, RS (LIPPINCOTT WILLIAMS & WILKINS, 2019-06-01)
    • Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism. 

      Kandaswamy, R; Sava, GP; Speedy, HE; Beà, S; Martín-Subero, JI; Studd, JB; Migliorini, G; Law, PJ; Puente, XS; Martín-García, D; Salaverria, I; Gutiérrez-Abril, J; López-Otín, C; Catovsky, D; Allan, JM; Campo, E; Houlston, RS (2016-08-11)
      Chronic lymphocytic leukemia (CLL) is an adult B cell malignancy. Genome-wide association studies show that variation at 15q15.1 influences CLL risk. We deciphered the causal variant at 15q15.1 and the mechanism by which ...
    • Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. 

      Li, N; Johnson, DC; Weinhold, N; Kimber, S; Dobbins, SE; Mitchell, JS; Kinnersley, B; Sud, A; Law, PJ; Orlando, G; Scales, M; Wardell, CP; Försti, A; Hoang, PH; Went, M; Holroyd, A; Hariri, F; Pastinen, T; Meissner, T; Goldschmidt, H; Hemminki, K; Morgan, GJ; Kaiser, M; Houlston, RS (2017-09)
      Multiple myeloma (MM) is a malignancy of plasma cells. Genome-wide association studies have shown that variation at 5q15 influences MM risk. Here, we have sought to decipher the causal variant at 5q15 and the mechanism by ...
    • Genetic predisposition to prostate cancer. 

      Benafif, S; Eeles, R (2016-12)
      <h4>Introduction</h4>Prostate cancer (PrCa) is the commonest non-cutaneous cancer in men in the UK. Epidemiological evidence as well as twin studies points towards a genetic component contributing to aetiology.<h4>Sources ...
    • Genetic predisposition to prostate cancer: an update. 

      Ni Raghallaigh, H; Eeles, R (2021-01-24)
      Improvements in DNA sequencing technology and discoveries made by large scale genome-wide association studies have led to enormous insight into the role of genetic variation in prostate cancer risk. High-risk prostate ...